Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Mantle Cell Lymphoma
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Non-Hodgkin’s Lymphoma (1034
)
Diffuse Large B Cell Lymphoma (374
)
T Cell Non-Hodgkin Lymphoma (117
)
Small Lymphocytic Lymphoma (106
)
Follicular Lymphoma (85
)
Peripheral T-cell Lymphoma (71
)
Lymphoplasmacytic Lymphoma (64
)
Marginal Zone Lymphoma (40
)
Burkitt Lymphoma (20
)
Cutaneous T-cell Lymphoma (18
)
Mediastinal B Cell Lymphoma (10
)
Non-Hodgkin’s Lymphoma (1034
)
Diffuse Large B Cell Lymphoma (374
)
T Cell Non-Hodgkin Lymphoma (117
)
Small Lymphocytic Lymphoma (106
)
Follicular Lymphoma (85
)
Peripheral T-cell Lymphoma (71
)
Lymphoplasmacytic Lymphoma (64
)
Marginal Zone Lymphoma (40
)
Burkitt Lymphoma (20
)
Cutaneous T-cell Lymphoma (18
)
Mediastinal B Cell Lymphoma (10
)
›
Associations
(124)
News
Trials
Search handles
@AaronGoodman33
@Abdallah81MD
@DrJFriedberg
@Dr_RShatsky
@Fer_martinmoro
@MKD_BMT
@albertomussetti
@aljurf100
@chanyooncheah
@graham74GC
@hematologo
@majorajay
@michaelwangmd
@rajuan_27
@smbenlazar
@timfenske
@tobyeyre82
Search handles
@AaronGoodman33
@Abdallah81MD
@DrJFriedberg
@Dr_RShatsky
@Fer_martinmoro
@MKD_BMT
@albertomussetti
@aljurf100
@chanyooncheah
@graham74GC
@hematologo
@majorajay
@michaelwangmd
@rajuan_27
@smbenlazar
@timfenske
@tobyeyre82
Filter by
Latest
9ms
These two MD Anderson docs delivered the best news today to my hubbs. Continued remission! Who in the world cares more about mantle cell lymphoma? @michaelwangmd Charles Gaulin MD @MDAndersonNews #mantlecelllymphoma (@nanswa1)
9 months ago
Clinical
9ms
In this @Medscape podcast, our Dr. Loretta Nastoupil discusses the landscape of CAR T cell therapy, including lessons from clinical trials, recent developments of CD19, mantle cell lymphoma and more. Listen here: https://t.co/JSqGs9GBCf @LNastoupilMD #lymphoma #EndCancer (@MDAndersonNews)
9 months ago
Clinical • CAR T-Cell Therapy
9ms
Our @CULymphoma lead Dr. @mana1981 contributed to a multicenter study of venetoclax in relapsed mantle cell lymphoma, now published @BloodAdvances. #lymsm cc @YazeedSawalha @othman_salim @PallawiTorkaMD @BrianHill_MDPhD https://t.co/v47FuVAw0z (@CULymphoma)
9 months ago
Clinical
|
Venclexta (venetoclax)
9ms
Young male patient with mantle cell lymphoma del17p+, tp53 mut not detected, refractory to R-DHAP, now on R-ibrutinib. Would you go for allo in Cr1? No pirto or cart available in 🇦🇷 in case of relapse. @tobyeyre82 @michaelwangmd (@laura_korin)
9 months ago
Clinical
|
Imbruvica (ibrutinib)
9ms
Great presentation by Dr. Javier Muñoz on Mantle Cell lymphoma at the Mayo Clinic and National Kapodistrian Univ. Of Athens Hematology & Oncology Course in Athens, Greece @MayoCancerCare @MayoClinic @YiLinMDPhD @ARosenthalDO (@MKD_BMT)
9 months ago
9ms
WATCH: @kmaddmd, and @DanilovLab, of @cityofhope, discuss the use of Bruton tyrosine kinase inhibitors for the treatment of relapsed/refractory mantle cell lymphoma. #lymsm #hematology https://t.co/0Q98E0H0Iz (@OncLive)
9 months ago
9ms
Liso-Cel Elicits Rapid, Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma @michaelwangmd @MDAndersonNews @icmlugano #icml17 #lymsm https://t.co/uwGxyFez6f (@OncLive)
9 months ago
Breyanzi (lisocabtagene maraleucel)
10ms
DEBATE #1 Best therapy in aggressive mantle cell lymphoma: Time for frontline chemotherapy-free regimens? ✅ YES - @michaelwangmd ❌ NO - Martin Dreyling (@Fer_martinmoro)
10 months ago
10ms
1st report antiCD19 CART Liso-cel in r/r mantle cell lymphoma (>1 prior line). TRANSCEND NHL 001 @michaelwangmd Astonishing results (even although influenced by Covid pandemia) & better safety profile related with CRS/neurologic than which reported with brexu-cel #LBA3 #17ICML (@Fer_martinmoro)
10 months ago
Clinical
|
Breyanzi (lisocabtagene maraleucel)
10ms
TRANSCEND NHL 001 Liso-cel for mantle cell lymphoma @michaelwangmd #17ICML - 88 pts - median 3 prior lines - 94% prior BTKi - 23% TP53mut - 8% CNS disease (@Eddie_Cliff)
10 months ago
Clinical
|
Breyanzi (lisocabtagene maraleucel)
10ms
Go, go @michaelwangmd @MDAndersonNews!! Proud of our Mantle Cell Lymphoma program! Thank you @DrSwami_Iyer for your support. Cheers to the Rare Lymphoma Section! (@jaymbsanycgmai1)
10 months ago
10ms
Mantle cell lymphoma debate @michaelwangmd @MDAndersonNews vs Martin Dreyling @LMU_Muenchen Exciting to see the progress with novel, chemo-free regimens, especially amongst groups such as TP53mut But for most MCL patients chemo combinations still the way to go #17ICML (@Eddie_Cliff)
10 months ago
Clinical
10ms
#17ICML . Debate time! Mantle cell lymphoma. @michaelwangmd vs. Dr. Dreyling. (@hematologo)
10 months ago
10ms
Dr M. Wang @michaelwangmd defending the use of chemo-free regimens as fronline approach for #mantlecelllymphoma at #17ICML . So inspiring! (@gaelroueBCN)
10 months ago
10ms
Jain et al - acala ritux first line Rx in elderly mantle cell lymphoma - 50 pts, med age 69y (all > 65) - v low cardiac events on this study but much stricter cardiac eligibility criteria than for IR 1L study - 2y PFS and PS: 92% and 96% Very impressive results #17ICML (@graham74GC)
10 months ago
Clinical
10ms
Allo-SCT still has a role in TP53mut mantle cell lymphomas. Looking forward to having CART available in Spain 🙏 #17ICML (@Fer_martinmoro)
10 months ago
10ms
Post-BTK inhibitor mantle cell lymphoma: When is CAR-T not the answer? https://t.co/78jOygTx7p A commentary on the SCHOLAR 2 study https://t.co/4QNzanQ0t8 #lymsm @tobyeyre82 @gilles_salles (@BrJHaem)
10 months ago
10ms
🟣#MCL #MantleCellLymphoma webinar series 👉🏽Final session on WED MAY 31 👉🏽Registration 🔗 https://t.co/zBT0mFC8vX Thanks to @AstraZeneca @lymphomaOz @clementinesar @PaolaGhione_MD @SilviaBea1 #BarbaraBurroni (@WomenInLymphoma)
10 months ago
10ms
Mantle cell lymphoma presenting as lymphomatoid (or lymphomatous) polyposis in an ileal nodule, CD20+ CD5+ CyclinD1+ CD10-. Nice images. (@RZitwer)
10 months ago
CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • CD5 (CD5 Molecule) • MME (Membrane Metalloendopeptidase)
10ms
From a new treatment option for mantle cell lymphoma to protein variants that trigger tumor cell death to insights on sickle cell trait and renal medullary carcinoma, learn the latest: https://t.co/jcK7ESjPzM @MichaelWangMD @LabGenovese @PavlosMsaouel #EndCancer (@MDAndersonNews)
10 months ago
Tumor cell
10ms
Blastoid variant of mantle cell lymphoma. (@hitmanogo)
10 months ago
11ms
Pirtobrutinib in Covalent BTK-Inhibitor Pre-treated Mantle Cell Lymphoma https://t.co/BTioRLqCRo (@albertomussetti)
11 months ago
Jaypirca (pirtobrutinib)
11ms
Most important progress in the treatment of #mantlecelllymphoma in2023. (@michaelwangmd)
11 months ago
11ms
Hot from press ! Patient is asking for this drug every day. Pirtobrutinib in Covalent BTK-Inhibitor Pre-treated Mantle Cell Lymphoma | Journal of Clinical Oncology https://t.co/I40VpWCkxD (@michaelwangmd)
11 months ago
Clinical
|
Jaypirca (pirtobrutinib)
11ms
Good news indeed for patients with #MantleCellLymphoma, a population with typically a poor prognosis. (@lwelmore0320)
11 months ago
Clinical
11ms
Big lymphoma news! ▶️▶️ Pivotal R/R #MCL data now online in @JCO_ASCO #Pirtobrutinib in Covalent BTK-Inhibitor Pre-treated Mantle Cell Lymphoma https://t.co/V97XPkvXKb (@tobyeyre82)
11 months ago
Jaypirca (pirtobrutinib)
11ms
✔️ 18 de maio Simpósio Satélite Lilly 13h45 às 14h45 - palestrante - Unmet need in mantle cell lymphoma Sala Médica 17H29 às 17H47 - palestrante - Raspando a cabeleira da tricoleucemia (leucemia de células cabeludas): quais são as melhores máquinas de corte? (@danielleleao10)
11 months ago
11ms
Results from a Phase 1/2 Study of Tandem, Bispecific Anti-CD20/Anti-CD19 (LV20.19) CAR T-Cells for Mantle Cell Lymphoma https://t.co/UwLVhuzdtV 1/9318/487701/Results-from-a-Phase-1-2-Study-of-Tandem/ #lymsm (@smbenlazar)
11 months ago
CAR T-Cell Therapy
11ms
Really appreciate this series on Mantle Cell Lymphoma. Nice to hear a MCL expert sound so optimistic and even use the "c" (Cure) word. Hoping to stay alive long enough to see that come to fruition. Need better insurance so I can get to @AndreGoyMD to increase my odds... (@Bp53Ki6791905)
11 months ago
Reimbursement • US reimbursement
11ms
Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in US Lymphoma CAR T Consortium https://t.co/eBoLaipL6a (@DrJFriedberg)
11 months ago
Tecartus (brexucabtagene autoleucel)
11ms
Nice summar slide by Dr Anita Kumar @MSK_DeptOfMed outlining the timeline of mantle cell lymphoma FDA drug approvals. #MSKCME #MSKLymphomaCME (@PallawiTorkaMD)
11 months ago
FDA event
12ms
Polatuzumab-bendamustine-rituximab as bridge to CD19-directed CAR T cells in mantle cell lymphoma refractory to ibrutinib and venetoclax https://t.co/SqJMV0NMFw (@smbenlazar)
12 months ago
CAR T-Cell Therapy
|
CD19 (CD19 Molecule)
|
Venclexta (venetoclax) • Imbruvica (ibrutinib) • Rituxan (rituximab) • bendamustine • Polivy (polatuzumab vedotin-piiq)
1year
Mantle cell lymphoma is CD10 negative and usually CD5+/CD23+ unlike CLL which is CD5+/CD23+ and also CD10-. (@DrQadeerBaloch)
1 year ago
CD5 (CD5 Molecule) • MME (Membrane Metalloendopeptidase) • FCER2 (Fc Fragment Of IgE Receptor II)
1year
Treatment approaches for patients with TP53-mutated mantle cell lymphoma - The Lancet Haematology https://t.co/4aicEko11q (@aljurf100)
1 year ago
Clinical
|
TP53 (Tumor protein P53)
|
TP53 mutation
1year
@niravshahmd presenting very exciting data on 14 R/R mantle cell lymphoma patients treated with CD19/20 CAR-T with mostly 8 day manufacturing on site. Proud to be part of this team! @MediHumdani #Tandem23 (@timfenske)
1 year ago
Clinical
|
CD19 (CD19 Molecule)
1year
Please join us in the Sabel room where Dr Nirav Shah will be presenting our exciting data on dual CD19/20 CART with point of care production and 8-12 day production for R/R mantle cell lymphoma. Starting in 5-10 min (3:10 - 3:15 pm or so). #TandemTCT (@timfenske)
1 year ago
CD19 (CD19 Molecule)
1year
Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma: https://t.co/g4M1OyqIhN @michaelwangmd @MDAndersonNews #Hematology #Therapeutics (@jclinicalinvest)
1 year ago
MALT1 (MALT1 Paracaspase)
1year
NEW: @thomaseliotlew, @AdrianMinson, and colleagues review available data on the management of patients with TP53-mutated mantle cell lymphoma and present a treatment strategy that prioritises trials and early use of cellular therapies. #lymsm https://t.co/LfXptH3GWb (@TheLancetHaem)
1 year ago
Clinical • Review
|
TP53 (Tumor protein P53)
|
TP53 mutation
over1year
Mantle cell lymphoma, Blastoid varient with MYC expression Flow pattern: CD 20 strong + CD 5 + CD 10 - CD 23 +/- CD 200 - (@Manea__Q1)
over 1 year ago
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CD20 (Membrane Spanning 4-Domains A1) • CD200 (CD200 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
|
MYC expression
over1year
Blastoid mantle cell lymphoma. CD20+ CD5+ CD3- K or L positive Ki67: High (@redmooney)
over 1 year ago
CD20 (Membrane Spanning 4-Domains A1) • CD5 (CD5 Molecule)
over1year
Blastic mantle cell lymphoma with MYC and BCL6 expression (@documangp)
over 1 year ago
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL6 (B-cell CLL/lymphoma 6)
|
MYC expression
over1year
Mantle cell lymphoma CD19+ CD5+ CD23- CD200- CD20 strong CD79b strong (@felipemagalf)
over 1 year ago
CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule) • CD79B (CD79b Molecule) • CD5 (CD5 Molecule) • CD200 (CD200 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login